Page last updated: 2024-08-23

bezafibrate and Obesity

bezafibrate has been researched along with Obesity in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (9.09)18.2507
2000's13 (59.09)29.6817
2010's6 (27.27)24.3611
2020's1 (4.55)2.80

Authors

AuthorsStudies
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM1
Honda, A; Ishii, I1
Aguila, MB; Correia, AL; dos Anjos, TL; Faria, Tda S; Mandarim-de-Lacerda, CA1
Aguila, MB; Bargut, TC; de Carvalho, SN; Magliano, DC; Mandarim-de-Lacerda, CA; Souza-Mello, V1
Aoki, K; Goto, T; Iijima, Y; Kawada, T; Kim, YI; Shibata, D; Suda, K; Suzuki, H; Takahashi, H; Takahashi, N; Takino, A; Yamazaki, Y1
Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E1
Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA1
Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K1
Gao, Z; Jia, W; Li, H; Xu, A; Ye, J; Ye, X; Zhang, J1
Mori, Y1
Bamberg, K; Camejo, G; Dahllöf, B; Kjellstedt, A; Ljung, B; Oakes, ND; Ostling, J; Svensson, L1
Nakagawa, M; Onishi, T; Saibara, T; Saika, K; Shizuta, Y; Sugiura, T; Takeda, K; Toda, K1
Jia, D; Otsuki, M1
Jia, D; Otani, M; Otsuki, M; Yamamoto, M1
Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N; Tokutate, Y1
Brand, CL; Pickavance, LC; Wassermann, K; Wilding, JP1
Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N1
Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Leor, J; Motro, M; Schwammenthal, E; Shemesh, J; Tanne, D; Tenenbaum, A1
Perkins, JD1
Miller, M1
Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I1
de Ridder, JH; Jerling, JC; Kellerman, JA; Nel, CJ; Oosthuizen, W; Smuts, CM; van der Nest, DG; Veldman, FJ; Venter, CS; Vermaak, WJ; Vorster, HH1

Reviews

3 review(s) available for bezafibrate and Obesity

ArticleYear
The PPARs: from orphan receptors to drug discovery.
    Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4

    Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2000
[The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2022, Volume: 142, Issue:12

    Topics: Bezafibrate; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Obesity; PPAR alpha

2022
[Uncoupling protein-3 in skeletal muscle].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 7

    Topics: Animals; Bezafibrate; Carrier Proteins; Diabetes Mellitus; Energy Metabolism; Glucose; Humans; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Lipid Metabolism; Mitochondrial Proteins; Muscle, Skeletal; Obesity; Uncoupling Protein 3

2002

Trials

1 trial(s) available for bezafibrate and Obesity

ArticleYear
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
    European heart journal, 2005, Volume: 26, Issue:19

    Topics: Adult; Aged; Bezafibrate; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Obesity; Prospective Studies; Treatment Outcome

2005

Other Studies

18 other study(ies) available for bezafibrate and Obesity

ArticleYear
Adverse association between obesity and menopause in mice treated with bezafibrate, a pan peroxisome proliferator-activated receptor agonist.
    Menopause (New York, N.Y.), 2013, Volume: 20, Issue:12

    Topics: Adiposity; Animals; Bezafibrate; Diet, High-Fat; Female; Hypolipidemic Agents; Islets of Langerhans; Menopause; Mice; Mice, Inbred C57BL; Obesity; Ovariectomy; Peroxisome Proliferator-Activated Receptors

2013
Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: Adipocytes; Adipose Tissue, White; Animals; Bezafibrate; Body Weight; Carbohydrate Metabolism; Cell Size; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Energy Metabolism; Fatty Liver; Female; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR alpha; PPAR gamma; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Prenatal Nutritional Physiological Phenomena; Sterol Regulatory Element Binding Protein 1

2013
Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor α agonist.
    Bioscience, biotechnology, and biochemistry, 2013, Volume: 77, Issue:11

    Topics: Animals; Bezafibrate; Chromatography, Liquid; Fatty Acids, Nonesterified; Gene Expression; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Mass Spectrometry; Mice; Mice, Obese; Obesity; PPAR alpha; Stearoyl-CoA Desaturase

2013
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Molecular metabolism, 2017, Volume: 6, Issue:3

    Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors

2017
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
    Pancreas, 2009, Volume: 38, Issue:3

    Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain

2009
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    European journal of pharmacology, 2011, Jul-15, Volume: 662, Issue:1-3

    Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate

2011
Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.
    Diabetes, 2012, Volume: 61, Issue:4

    Topics: Animals; Bezafibrate; Butyrates; Dietary Fats; Fibroblast Growth Factors; Gene Expression Regulation; HEK293 Cells; Hep G2 Cells; Histone Deacetylases; Humans; Hypolipidemic Agents; Liver; Male; Mice; Mice, Knockout; Mice, Obese; Obesity; PPAR alpha; Promoter Regions, Genetic; RNA, Messenger

2012
AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
    Journal of lipid research, 2002, Volume: 43, Issue:11

    Topics: Alkanesulfonates; Animals; Bezafibrate; Carbohydrate Metabolism; Cinnamates; Diabetes Mellitus; Fatty Acids; Glucose; Humans; Insulin Resistance; Lipid Metabolism; Male; Mass Spectrometry; Mice; Mice, Obese; Molecular Structure; Obesity; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Cells, Cultured

2002
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
    The Journal of endocrinology, 2003, Volume: 176, Issue:2

    Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Models, Animal; Obesity; Pioglitazone; Testosterone; Thiazoles; Thiazolidinediones; Triglycerides

2003
Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.
    Pancreas, 2003, Volume: 26, Issue:3

    Topics: Actins; Animals; Bezafibrate; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Hypolipidemic Agents; Insulin; Lipids; Obesity; Organ Size; Pancreas; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Transcription Factors

2003
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
    Metabolism: clinical and experimental, 2004, Volume: 53, Issue:4

    Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypolipidemic Agents; Immunohistochemistry; Insulin; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Lipids; Obesity; Pancreas; Rats; Rats, Inbred OLETF; Triglycerides

2004
Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
    Journal of atherosclerosis and thrombosis, 2004, Volume: 11, Issue:4

    Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids; Gene Expression Regulation; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Male; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Obesity; PPAR alpha; PPAR delta; Rats; Rats, Inbred Strains; RNA, Messenger; Thyroid Hormones; Uncoupling Agents; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Viscera

2004
The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
    British journal of pharmacology, 2005, Volume: 144, Issue:3

    Topics: Adipose Tissue; Animals; Bezafibrate; Body Composition; Body Weight; Diabetes Mellitus; Diet; Energy Metabolism; Glucose Clamp Technique; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Obesity; Organ Size; Oxazines; Pancreas; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Leptin; Thiazolidinediones

2005
Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
    Endocrine, 2004, Volume: 25, Issue:3

    Topics: Adiponectin; Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Cholesterol, VLDL; Chylomicrons; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypolipidemic Agents; Intercellular Signaling Peptides and Proteins; Male; Obesity; Rats; Rats, Inbred OLETF; RNA, Messenger

2004
Saying "Yes" to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2006, Volume: 12, Issue:6

    Topics: Bezafibrate; Exercise Therapy; Fatty Liver; Humans; Hypolipidemic Agents; Liver Transplantation; Living Donors; Obesity

2006
Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.
    Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:4

    Topics: Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Middle Aged; Myocardial Infarction; Obesity; Time Factors; Triglycerides

2006
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy].
    Presse medicale (Paris, France : 1983), 1995, Jan-07, Volume: 24, Issue:1

    Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides

1995
Soluble-fibre concentrate lowers plasminogen activator inhibitor-1 in baboons (Papio ursinus).
    The British journal of nutrition, 1997, Volume: 78, Issue:4

    Topics: Analysis of Variance; Animals; Bezafibrate; Diet; Dietary Fiber; Glucose; Hypolipidemic Agents; Lipid Metabolism; Lipids; Lipoproteins; Liver; Male; Obesity; Papio; Plasminogen Activator Inhibitor 1; Random Allocation; Triglycerides

1997